Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

ACS Nano, Journal Year: 2024, Volume and Issue: 18(3), P. 1820 - 1845

Published: Jan. 9, 2024

The blood–brain barrier (BBB) is a specialized semipermeable structure that highly regulates exchanges between the central nervous system parenchyma and blood vessels. Thus, BBB also prevents passage of various forms therapeutic agents, nanocarriers, their cargos. Recently, many multidisciplinary studies focus on developing cargo-loaded nanoparticles (NPs) to overcome these challenges, which are emerging as safe effective vehicles in neurotheranostics. In this Review, first we introduce anatomical physiological functions BBB. Second, present endogenous exogenous transport mechanisms by NPs cross We report nanomaterials, carriers, cargos, with detailed uptake permeability characteristics. Third, describe effect regulating size, shape, charge, surface ligands affect permeability, can be exploited enhance promote classify typical functionalized nanomaterials developed for crossing. Fourth, provide comprehensive review recent progress functional polymeric applications multimodal bioimaging, therapeutics, drug delivery. Finally, conclude discussing existing directions, future perspectives employing

Language: Английский

---

Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 22, 2025

Parkinson’s disease is a progressive neurodegenerative that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment approaches primarily focus on symptom management, employing pharmacological, non-pharmacological, surgical methods. However, these treatments often result in fluctuating symptoms, side effects, progression. Here, the authors have reviewed emerging field of nanomedicine as promising path for treatment, emphasizing its potential to overcome limitations traditional therapies. Nanomedicine utilizes nanoparticles targeted drug delivery, leveraging their small size high surface area volume ratio cross blood-brain barrier deliver therapeutic agents directly affected brain regions. Various nanoparticles, including lipid-based, polymeric, metallic, carbon-based, shown treatment. Additionally, nanocarrier systems like liposomes, nanogels, dendrimers, solid lipid offer controlled sustained release agents, enhancing bioavailability reducing effects. This review provides insights into pathophysiology disease, highlighting mechanisms neurodegeneration, role alpha-synuclein, disruption pathways. It further discusses application gene therapy conjunction with interventions.

Language: Английский

---

MicroRNAs in Parkinson’s disease: From pathogenesis to diagnostics and therapeutic strategies

Neuroscience, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Brain gene therapy with Trojan horse lipid nanoparticles

Trends in Molecular Medicine, Journal Year: 2023, Volume and Issue: 29(5), P. 343 - 353

Published: March 11, 2023

The COVID-19 mRNA vaccine was developed by the scalable manufacture of lipid nanoparticles (LNPs) that encapsulate within lipid. There are many potential applications for this large nucleic acid delivery technology, including plasmid DNA gene therapy. However, therapy brain requires LNP across blood-brain barrier (BBB). It is proposed LNPs could be reformulated conjugation receptor-specific monoclonal antibodies (MAbs) to surface. MAb acts as a molecular Trojan horse trigger receptor-mediated transcytosis (RMT) BBB and subsequent localization nucleus transcription therapeutic gene. enable new approaches brain.

Language: Английский

---

Levodopa-loaded nanoparticles for the treatment of Parkinson's disease

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 360, P. 212 - 224

Published: June 25, 2023

Parkinson's disease (PD) is a neurodegenerative disorder characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) resulting dopamine (DA) deficiency, which manifests itself motor symptoms including tremors, rigidity and bradykinesia. Current PD treatments aim at symptom reduction through oral delivery levodopa (L-DOPA), precursor DA. However, L-DOPA to brain inefficient increased dosages are required as progresses, serious side effects like dyskinesias. To improve treatment efficacy reduce effects, recent research focuses on encapsulation into polymeric- lipid-based nanoparticles (NPs). These formulations can protect from systemic decarboxylation DA central nervous system. Additionally, NPs be modified with proteins, peptides antibodies specifically targeting blood-brain barrier (BBB), thereby reducing free Alternative approaches for NP-encapsulated include intravenous (IV) administration, transdermal using adhesive patches direct intranasal facilitating therapeutic concentrations brain. This review provides an overview advances NP-mediated brain, debates challenges future perspectives field.

Language: Английский

---

Analytical assessment of a novel RP-HPLC method for the concurrent quantification of selected pharmaceutical drugs levodopa and carbidopa using eight greenness metrics comparing to the lean six sigma approach

Sustainable Chemistry and Pharmacy, Journal Year: 2023, Volume and Issue: 36, P. 101291 - 101291

Published: Oct. 13, 2023

Language: Английский

---

Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management

Pharmaceutics, Journal Year: 2023, Volume and Issue: 16(1), P. 58 - 58

Published: Dec. 29, 2023

Alzheimer's disease, a progressive neurodegenerative condition, is characterized by gradual decline in cognitive functions. Current treatment approaches primarily involve the administration of medications through oral, parenteral, and transdermal routes, aiming to improve function alleviate symptoms. However, these treatments face limitations, such as low bioavailability inadequate permeation. Alternative invasive methods, while explored, often entail discomfort require specialized assistance. Therefore, development non-invasive efficient delivery system crucial. Intranasal has emerged potential solution, although it constrained unique conditions nasal cavity. An innovative approach involves use nano-carriers based on nanotechnology for intranasal delivery. This strategy overcome current limitations providing enhanced bioavailability, improved permeation, effective traversal blood-brain barrier, extended retention within body, precise targeting brain. The comprehensive review focuses advancements designing various types nano-carriers, including polymeric nanoparticles, metal lipid liposomes, nanoemulsions, Quantum dots, dendrimers. These are specifically tailored therapeutic agents aimed at combatting disease. In summary, utilization systems show significant surmounting constraints disease strategies. Nevertheless, essential acknowledge regulatory well toxicity concerns associated with this route; meticulous consideration required when engineering carrier. underscores revolutionize management highlights importance addressing considerations safe implementations. Embracing could lead substantial field treatment.

Language: Английский

---

Looking Back, Moving Forward: Lipid Nanoparticles as a Promising Frontier in Gene Delivery

ACS Pharmacology & Translational Science, Journal Year: 2023, Volume and Issue: 6(11), P. 1561 - 1573

Published: Oct. 24, 2023

Lipid nanoparticles (LNPs) have shown remarkable success in delivering genetic materials like COVID-19 LNP vaccines, such as mRNA-1273/SpikeVax by Moderna and BNT162b2/Comirnaty BioNTech/Pfizer, well siRNA for rare inherited diseases, Onpattro from Alnylam Pharmaceuticals. These LNPs are advantageous since they minimize side effects, target specific cells, regulate payload delivery. There has been a surge of interest these particles due to their stories; however, we still do not know much about how work. This perspective will recapitulate the evolution lipid-based gene delivery, starting with Felgner's pioneering 1987 PNAS paper, which introduced initial DNA-transfection method utilizing synthetic cationic lipid. Our journey takes us early 2020s, time when advancements bionano interactions enabled create biomimetic lipoplexes characterized ability evade capture immune cells vivo. Through this overview, propose leveraging previous achievements assist formulating improved research goals optimizing medical conditions infectious cancer, heritable disorders.

Language: Английский

---

Dopamine-loaded chitosan-coated solid lipid nanoparticles as a promise nanocarriers to the CNS

Neuropharmacology, Journal Year: 2024, Volume and Issue: 249, P. 109871 - 109871

Published: Feb. 25, 2024

Language: Английский

---

Novel Nose-to-brain delivery of carbenoxolone via mucoadhesive solid lipid nanoparticles for Parkinson’s symptoms management: In vitro and in vivo evaluation in a rotenone-induced rat model

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: 670, P. 125197 - 125197

Published: Jan. 8, 2025

Language: Английский

---